The Company reported a net loss for the 2008 first quarter of $1.1 million, or $0.02 per share, compared with a net loss of $3.3 million, or $0.06 per share, for the same prior year period.
As of March 31, 2008, the Company had approximately $90.8 million in current and non-current unrestricted cash, cash equivalents and marketable securities.
"We are pleased to end the 2008 first quarter with nearly the same amount of cash, cash equivalents and marketable securities that we had at the end of 2007, given that we have considerably advanced the development of MP-470, our clinical-stage tyrosine kinase (TK) inhibitor and Rad51 suppressor, and SGI-1776 and S-110, two of our pre-clinical stage compounds," said Dr. James Manuso, SuperGen's President and Chief Executive Officer. "We are on schedule to begin Phase 1 clinical trials with SGI-1776 before year-end. Dacogen royalty revenues have continued to largely offset our operating expenses and productivity has been further enhanced across the discovery and development functions."
2008 Revised Financial Guidance
The Company expects to report royalty revenue for 2008 in a range from
$32 million to $35 million. The Company's royalty revenue is initially
based on the annual end user guidance of approximately $157 million for
2008 provided by Eisai Co., Ltd. in their quarterly conference call in
early February 2008. The C
|SOURCE SuperGen Inc.|
Copyright©2008 PR Newswire.
All rights reserved